Sirolimus, Trastuzumab Well-Tolerated in Breast Cancer Progression with Prior Therapy
Combination sirolimus and trastuzumab is well-tolerated in metastatic HER2-positive breast cancer after disease progression.
Combination sirolimus and trastuzumab is well-tolerated in patients with metastatic human epidermal growth factor receptor (HER2)-positive breast cancer after disease progression with prior trastuzumab therapy, according to a study published in Breast Cancer Research and Treatment.
In a phase II trial, researchers led by Carlos Acevedo-Gadea, MD, of the Yale University School of Medicine administered sirolimus 6 mg oral daily along with a standard dose of trastuzumab weekly or every three weeks.
In total, eleven patients were evaluated for safety, and nine were evaluated for response assessment.
RELATED: Paclitaxel, Trastuzumab New Standard of Care for Early-Stage Breast Cancer
They found that five patients who were treated for 101 weeks had achieved stable disease as best response, while one patient who received eight cycles achieved a partial response.
Overall response rate amounted to 11 percent while clinical benefit rate was 44%.
“Sirolimus 6 mg administered daily with trastuzumab appears to be well-tolerated in patients with metastatic HER2-positive breast cancer following disease progression on prior trastuzumab therapy, with evidence of disease activity,” the authors concluded.